What is Aprinoia Therapeutics Inventory-to-Revenue?
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Aprinoia Therapeutics's Average Total Inventories for the quarter that ended in Jun. 2023 was $0.00 Mil. Aprinoia Therapeutics's Revenue for the
six
months ended in Jun. 2023 was $9.03 Mil.
Aprinoia Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 0.00.
Aprinoia Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2023
stayed the same
from Dec. 2022 (0.00) to Dec. 2022 (0.00)
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Aprinoia Therapeutics Inventory-to-Revenue Historical Data
The historical data trend for Aprinoia Therapeutics's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Aprinoia Therapeutics Inventory-to-Revenue Chart
Aprinoia Therapeutics Annual Data
Trend
Dec21
Dec22
Inventory-to-Revenue
-
-
Aprinoia Therapeutics Semi-Annual Data
Dec21
Jun22
Dec22
Jun23
Inventory-to-Revenue
-
-
-
-
Competitive Comparison of Aprinoia Therapeutics's Inventory-to-Revenue
For the Biotechnology subindustry, Aprinoia Therapeutics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprinoia Therapeutics's Inventory-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Aprinoia Therapeutics's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Aprinoia Therapeutics's Inventory-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Aprinoia Therapeutics's Days Inventory for the
six
months ended in Jun. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aprinoia Therapeutics Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of Aprinoia Therapeutics's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APRI has been successfully added to your